Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Stenocare: Delivers on Key Strategic Initiatives - Analyst Group

STENOThird party research29.08.2024, 09.11

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
STENOCARE A/S (“STENOCARE” or the “Company”) has executed on several strategically important milestones during H1-24, including approval of the balanced oil in Denmark and the launch of premium products in Australia and Germany. However, higher product price subsidy has increased competition from Magistrel products in Denmark, and the market growth has been slower than expected which has affected sales. This has led us to update our financial forecasts for STENOCARE and with estimated net sales of DKK 30.2m by 2026, and with an applied P/S multiple of 4x, a potential present value per share of DKK 4.0 (8.8) is derived in a Base scenario. The updated valuation is a result of the updated forecasts, a multiple contraction in the industry as well as an increase in shares outstanding from capital raises.